Roche’s Genentech has terminated its multi-year collaboration with Adaptive Biotechnologies on cancer cell therapy development, ending a partnership valued at up to $2 billion. The alliance leveraged Adaptive’s TCR screening platform to identify personalized cancer therapies, with Genentech handling clinical development and commercialization. Adaptive will recognize $33.7 million in non-cash revenues from the agreement’s wind-down. Both companies expressed mutual respect, underscoring this as a strategic decision not related to safety concerns.